Skip to main content
S&P 5007,622.04+0.48%DOW52,132.60+0.08%NASDAQ26,210.04+0.88%BTC$75,816.00-0.81%ETH$2,396.09-1.28%GOLD$4,392.20+1.37%OIL$102.21-3.42%
Smart Investors Daily
Bionano Genomics, Inc. logo

NYSE · BNGO

Bionano Genomics, Inc.

Healthcare · Medical - Diagnostics & Research

$1.56

Down-$0.08 (-5.13%)

Updated Sep 16, 2026, 3:40 PM

SID Score

3.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
5.48M
P/E ratio
-0.23
Dividend yield
0.00%
52-week range
$1.00 – $2.23
Volume
39.78M
Avg. volume
721.42K

Price performance

BNGO price history

1M range · 20 trading sessions · Daily adjusted prices

BNGO closed at $1.56 after 20 trading sessions, up 32.20% for the selected period.

Last close
$1.56
Period change
+32.20%
Period low
$1.17
Period high
$1.56
Daily close
View OHLC price history
BNGO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$1.31$2.23$1.31$1.5639.78M
Sep 14, 2026$1.23$1.38$1.2143$1.33409.55K
Sep 11, 2026$1.21$1.24$1.20$1.2257.99K
Sep 10, 2026$1.18$1.24$1.16$1.20288.14K
Sep 9, 2026$1.19$1.22$1.18$1.1869.46K
Sep 8, 2026$1.21$1.2263$1.185$1.2087.37K
Sep 4, 2026$1.25$1.25$1.195$1.20177.45K
Sep 3, 2026$1.27$1.28$1.23$1.24191.72K
Sep 2, 2026$1.22$1.28$1.2038$1.27300.73K
Sep 1, 2026$1.21$1.22$1.17$1.22208.66K
Aug 31, 2026$1.18$1.22$1.15$1.22177.4K
Aug 28, 2026$1.23$1.24$1.16$1.17179.63K
Aug 27, 2026$1.21$1.25$1.20$1.21168.13K
Aug 26, 2026$1.24$1.26$1.205$1.21157.09K
Aug 25, 2026$1.22$1.26$1.201$1.25115.65K
Aug 24, 2026$1.22$1.25$1.18$1.22133.38K
Aug 21, 2026$1.22$1.26$1.18$1.20193.21K
Aug 20, 2026$1.22$1.24$1.19$1.21111.53K
Aug 19, 2026$1.18$1.25$1.18$1.23245.82K
Aug 18, 2026$1.21$1.21$1.14$1.18180.74K

Latest BNGO news

The latest Smart Investors Daily articles mentioning BNGO.

Stock researchCompany · Overview

BNGO research

Overview

Company profile and research snapshot.

Company profile

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$46.50
Implied upside
—
Analysts
—
BNGO recent ratings
DateFirmRatingTarget
Apr 13, 2026HC Wainwright & Co.Buy—
Nov 24, 2025HC Wainwright & Co.Buy—
Aug 18, 2025HC Wainwright & Co.Buy—
May 20, 2025Maxim GroupBuy—
Apr 9, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 10, 2026

Bionano Laboratories Announces Proposed Local Coverage Determination (LCD) from MolDX for Genome-Wide Detection of Structural Variants in Hematologic Neoplasms

SAN DIEGO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed test (LDTs), today announced that MolDX, a program that assesses molecular diagnostic technologies on behalf of Medicare Administrative Contractors (MACs), has issued a proposed Local Coverage Determination (LCD) for Genome-Wide Molecular Methodologies for the Detection of Copy Number Alterations and Structural Vari

Yahoo · Sep 8, 2026

Bionano Laboratories Announces New York State Department of Health Approval of Lab Developed Tests Based on Optical Genome Mapping

New York State Department of Health approval allows clinical use of optical genome mapping (OGM) based lab developed tests (LDTs) for patients with suspected genetic disease, reproductive disorders, and hematologic malignancies at University of Rochester MedicineSAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed test (LDTs), today announced that the New York State D

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By